stockrowRadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
- Revenue
- +25.0%
- EPS
- −47.4%
- Free cash flow
- −43.2%
- Total debt
- +21.2%
Quarter to June 2026, against a year earlier
Follow RDNT
Alert me
RadNet, Inc. (RDNT) Revenue
RadNet, Inc.'s revenue for fiscal 2025 was $2.0B, up 11.5% from $1.8B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.3B. Over the past ten years it has ranged from $809.6M (fiscal 2015) to $2.0B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. RadNet, Inc. ranks 16th of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.0B | 11.51% |
| FY2024 | $1.8B | 13.18% |
| FY2023 | $1.6B | 13.05% |
| FY2022 | $1.4B | 8.74% |
| FY2021 | $1.3B | 22.69% |
| FY2020 | $1.1B | (7.13%) |
| FY2019 | $1.2B | 18.36% |
| FY2018 | $975.1M | 5.74% |
| FY2017 | $922.2M | 4.26% |
| FY2016 | $884.5M | 9.25% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $622.7M | 8.18% |
| Mar 2026 | $575.6M | 5.10% |
| Dec 2025 | $547.7M | 4.75% |
| Sep 2025 | $522.9M | 4.95% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ICLR ICON PLC compare | $8.2B |
| RDNT RadNet, Inc. | $2.3B |
| QGEN QIAGEN N.V. compare | $2.1B |
| SHC Sotera Health Company compare | $1.2B |
| VCYT Veracyte, Inc. compare | $581.8M |
| CDNA CareDx, Inc. compare | $497.4M |
| BLLN BillionToOne, Inc. compare | $436.9M |
| ADPT Adaptive Biotechnologies Corporation compare | $298.0M |
| GRAL GRAIL, Inc. compare | $166.6M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RDNT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement